CRISPR Therapeutics raises $64m 'validating' uncertain patent position
This article was originally published in Scrip
CRISPR Therapeutics, which is focused on developing drugs using CRISPR-Cas9 gene-editing technology, has added additional funds to its series A and series B rounds, which now total $89m. The "heavily oversubscribed" financings were led by GSK's venture arm SR One and Celgene, respectively, and included new investors New Enterprise Associates and Abingworth, along with founding investor Versant Ventures. The fresh cash includes $35m of new series A and $29m of new series B funds.
You may also be interested in...
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.